Immunohistochemical study of the EGFR and HER-2 expression in melanomas, Merkel cell carcinomas and metastatic cutaneous squamous cell carcinomas;Étude immuno-histochimique de l'expression de EGFR et HER-2 dans les mélanomes, les carcinomes de Merkel et les carcinomes épidermoïdes cutanés métastatiques

Annales de Dermatologie et de Venereologie

Volumn 133, Issue 3, 2006, Pages 274-276

  Maubec, E ^a   Duvillard, P ^b   Velasco, V ^b   Crickx, B ^a   Avril, M F ^b  

^a BICHAT HOSPITAL   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; CELL INFILTRATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MELANOMA; MERKEL CELL TUMOR; METASTASIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SQUAMOUS CELL CARCINOMA; TUMOR; LETTER; METABOLISM; SKIN TUMOR;

CARCINOMA, MERKEL CELL; CARCINOMA, SQUAMOUS CELL; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; NEOPLASM METASTASIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SKIN NEOPLASMS;

EID: 33745813583     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0151-9638(06)77555-X     Document Type: Article

References (20)

1. Vlahovic G, Crawford J. Activation of tyrosine kinases in cancer. Oncologist 2003;8:531-8.
2. De Wit PE, Moretti S, Koenders PG, Weterman MA, van Muijen GN, Gianotti B, et al. Increasing epidermal growth factor receptor expression in human melanocytic tumor progression. J Invest Dermatol 1992;99:168-73.
3. Real FX, Rettig WJ, Chesa PG, Melamed MR, Old LJ, Mendelsohn J. Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation. Cancer Res 1986;46:4726-31.
4. Inman JL, Kute T, White W, Pettenati M, Levine EA. Absence of HER2 overexpression in metastatic malignant melanoma. J Surg Oncol 2003;84:82-8.
5. Eliopoulos P, Mohammed MQ, Henry K, Retsas S. Overexpression of HER-2 in thick melanoma. Melanoma Res 2002;12:139-45.
6. Shimizu T, Izumi H, Oga A, Furumoto H, Murakami T, Ofuji R, et al. Epidermal growth factor receptor overexpression and genetic aberrations in metastatic squamous-cell carcinoma of the skin. Dermatology 2001;202:203-6.
7. Ahmed NU, Ueda M, Ichihashi M. Increased level of c-erbB-2/neu/HER-2 protein in cutaneous squamous cell carcinoma. Br J Dermatol 1997;136:908-12.
8. Chen IH, Chang JT, Liao CT, Wang HM, Hsieh LL, Cheng AJ. Prognostic significance of EGFR and Her-2 in oral cavity cancer in betel quid prevalent area cancer prognosis. Br J Cancer 2003;89:681-6.
9. Crone SA, Lee KF. Gene targeting reveals multiple essential functions of the neuregulin signalling system during development of the neuroendocrine and nervous systems. Ann N Y Acad Sci 2002;971:47-53.
10. Maubec E, Duvillard P, Velasco V, Crickx B, Avril M-F. Immunohistochemical analysis of EGFR and HER-2 in patients with metastatic squamous cell carcinoma of the skin. Anticancer Research 2005;25:1205-10.
11. Potti A, Moazzam N, Langness E, Sholes K, Tendulkar K, Koch M, et al. Immunohistochemical determination of HER-2/neu, c-Kit (CD117), and vascular endothelial growth factor (VEGF) overexpression in malignant melanoma. J Cancer Res Clin Oncol 2004;130:80-6.
12. Ma BB, Poon TC, To KF, Zee B, Mo FK, Chan CM, et al. Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma - a prospective study. Head Neck 2003;25:864-72.
13. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002;62:7350-6.
14. Rubin Grandis J, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998;90:824-32.
15. Magne N, Pivot X, Bensadoun RJ, Guardiola E, Poissonnet G, Dassonville O, et al. The relationship ofepidermal growth factor receptor levels to the prognosis of unresectable pharyngeal cancer patients treated by chemo-radiotherapy. Eur J Cancer 2001;37:2169-77.
16. Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortes-Funes H, Hitt R, et al. Cetuximab plus cisplatin/carboplatin is active in patients with recurrent/metastatic squamous cell carcinoma of the head and neck progressing on a same dose and schedule platinium-based regimen. Proc Am Soc Clin Oncol (Orlando, FL, May 17-22) 2002;20:900.
17. Kies MS, Arquette MA, Nabell L, Quinn D, Shin D, Needle MN, et al. Final report of the efficacy and safety of the anti-epidermal growth factor antibody Erbitux (IMC-C225), in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy. Proc Am Soc Clin Oncol (Orlando, FL, May 17-22) 2002;20:925.
18. Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, Knecht R, et al. Cetuximab monotherapy is active in patients with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SC-CHN): results of a phase II study. Proc Am Soc Clin Oncol (New Orleans, June 5-8) 2004;22:5502.
19. Burtness BA, Li Y, Flood W, Mattar BI, Forastiere AA. Phase III trial comparing cisplatin (C) + placebo (P) to C + anti-epidermal growth factor antibody (EGF-R) C225 in patients with metastatic/recurrent head & neck cancer (HNC). Proc Am Soc Clin Oncol (Orlando, FL, May 17-22) 2002;20:901.
20. Nemunaitis JJ, Eiseman I, Cunningham C, Lenehan P, Olson S, Bycott P, et al. A phase I trial of CI-1033, a pan-erbB tyrosine kinase inhibitor, given daily for 14 days every 3 weeks, in patients with advanced solid tumors. Proc Am Soc Clin Oncol (Chicago, May 31-June 3) 2003;21:974.